Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOPHIRIS BIO INC.SPHS · Entity 152909 | Director | June 27, 2019 | June 28, 2019 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | September 14, 2021 | September 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOPHIRIS BIO INC.
Report date June 27, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2029-06-26 | Direct | 20,000 |
Reported balance
After 2019-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-27 · Grant · Acquired 20,000 · Balance 20,000 F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program.
F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period.
Skye Bioscience, Inc.
Report date September 14, 2021 · Filed September 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2031-09-14 | Direct | 1,350,000 |
Reported balance
After 2021-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-14 · Grant · Acquired 150,000 · Balance 1,350,000 F1: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2021 Filed Sep 16, 2021 16:02 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantDirector Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001628280-21-018755 · wf-form4_163182251103569.xml · derivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 150,000 shares Expires 2031-09-14 F1 · derivative.exercise_date: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 14:52 UTC | Skye Bioscience, Inc. EMBI · Entity 8098 | GrantDirector Option Grant (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001640334-20-002026 · form4.xml · derivative · entry 2 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-08-07 F2 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 14:52 UTC | Skye Bioscience, Inc. EMBI · Entity 8098 | PurchaseCommon Stock | 500,000 | $50,000.00 | $25,000,000,000.00 |
DisclosureSEC source: 0001640334-20-002026 · form4.xml · nonDerivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 F1 · price: Private purchase transaction from Emerald Health Sciences at $0.10 per share. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 16:25 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-19-039480 · doc4.xml · derivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-26 F1 · security: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 12:19 UTC | Skye Bioscience, Inc. NMUS · Entity 8098 | GrantDirector Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-18-054867 · doc4.xml · derivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-10-10 F1 · derivative.exercise_date: The option will vest in equal monthly installments over a one-year period commencing on the date of grant. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:59 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001209191-18-039916 · doc4.xml · derivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-26 F1 · security: Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 16:34 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001209191-17-036797 · doc4.xml · derivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-29 F1 · security: Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 17:10 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | OtherCommon Shares | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147520 · doc4.xml · nonDerivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,188 Read SEC document |
| July 28, 2016 Filed Feb 8, 2017 19:51 UTC Amendment | SOPHIRIS BIO INC. SPHS · Entity 152909 | OtherCommon Shares | 1,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008918 · doc4a.xml · nonDerivative · entry 1 HEPPELL JAMES L · CIK 0001261140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,506 F1 · shares: On July 28, 2016, the Reporting Person received 1,318 shares pursuant to a liquidating distribution by Full Moon Consulting Corp. These shares were previously reported as indirectly held and this amendment is being filed to reflect the change from indirect to direct holding. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.